AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Kura Oncology Presents New Preliminary Data on Darlifarnib and Tipifarnib.
ByAinvest
Saturday, Oct 18, 2025 3:26 am ET1min read
Kura Oncology announced new preliminary data from its farnesyl transferase inhibitor (FTI) programs, darlifarnib and tipifarnib. Darlifarnib showed a 50% objective response rate and 80% disease control rate in a renal cell carcinoma cohort of an ongoing dose-escalation clinical trial. The FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies, and early clinical and preclinical data support darlifarnib's potential to enhance the clinical benefit of PI3Kα-, KRAS- and tyrosine kinase inhibitors.
Kura Oncology (Nasdaq: KURA) has released preliminary data from its farnesyl transferase inhibitor (FTI) programs, highlighting the potential of darlifarnib and tipifarnib in cancer treatment. The company presented these findings at the European Society for Medical Oncology (ESMO) Congress 2025, held from October 17 to 21, 2025, in Berlin, Germany, as detailed in a Stocktitan report .Darlifarnib Showcases Promising Results in Renal Cell Carcinoma
The preliminary data from Kura Oncology's ongoing dose-escalation clinical trial showed that darlifarnib, when combined with cabozantinib, produced an objective response rate (ORR) of 50% and a disease control rate (DCR) of 80% in a renal cell carcinoma (RCC) cohort. This is a significant finding, as the combination therapy demonstrated robust efficacy in a challenging patient population.
Tipifarnib's Potential in PIK3CA-Altered Head and Neck Squamous Cell Carcinoma
Additionally, tipifarnib, when combined with alpelisib, achieved an ORR of 47% in PIK3CA-altered head and neck squamous cell carcinoma (HNSCC). This result underscores the potential of tipifarnib in addressing innate and adaptive resistance pathways common to targeted oncology therapies.
FTI Mechanism and Clinical Benefits
The FTI mechanism addresses both innate and adaptive resistance pathways, which are common in targeted oncology therapies. Early clinical and preclinical data support darlifarnib's potential to enhance the clinical benefit of PI3Kα-, KRAS- and tyrosine kinase inhibitors. This suggests that FTIs like darlifarnib and tipifarnib could play a crucial role in improving treatment outcomes for various cancer types.
Investor Event and Webcast
Kura Oncology has scheduled a virtual investor event and webcast for October 18, 2025, to further discuss these findings and provide additional insights into their FTI programs.
Conclusion
The preliminary data from Kura Oncology's farnesyl transferase inhibitor programs, particularly darlifarnib, show promising results in renal cell carcinoma. The company's ongoing clinical trials and preclinical research continue to highlight the potential of FTIs in enhancing the efficacy of targeted oncology therapies. Investors and financial professionals should closely monitor these developments as they could significantly impact the future of cancer treatment.
References
-
- Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress —
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet